Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Illinois
Clinical trial register · United States · industry-sponsored

Clinical Trials in Illinois, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 65 Florida 54 New York 35 Illinois 32 Arizona 27
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca109 AbbVie103 Eli Lilly and Company70 Novartis Pharmaceuticals63 Merck Sharp & Dohme LLC62 Clear sponsor filter
State
California65 Florida54 New York35 Illinois32 Arizona27
All 46 states
Target enrolment
to

Trials with a site in Illinois

32 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Regeneron Pharmaceuticals
Phase 2
360
Alabama, California, Florida, Illinois, Kansas, Kentucky, New York, South Carolina
2026-07-28
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
265
Arizona, California, Florida, Illinois, Missouri, Texas
2026-07-20
Recruiting
Regeneron Pharmaceuticals
Phase 2
120
California, Florida, Georgia, Illinois, Kentucky, Michigan, Nebraska, New York
2026-04-14
Recruiting
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07154290Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
DrugsMarlotamig·Ubamatamab·Sarilumab
Regeneron Pharmaceuticals
Phase 2
300
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Illinois, Indiana
2026-03-18
Recruiting
Regeneron Pharmaceuticals
Phase 2
195
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-01-09
Recruiting
Regeneron Pharmaceuticals
Phase 3
2,000
California, Colorado, Florida, Illinois, Indiana, Kansas, Maryland, Massachusetts
2025-11-24
Recruiting
Regeneron Pharmaceuticals
Phase 2
297
Alabama, California, Florida, Illinois, Kansas, Kentucky, Massachusetts, Michigan
2025-05-28
Recruiting
Regeneron Pharmaceuticals
Phase 3
369
Arizona, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kentucky
2025-01-02
Active, closed
Regeneron Pharmaceuticals
Observational
368
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-11-22
Active, closed
Regeneron Pharmaceuticals
Phase 2
120
California, Illinois, Michigan, Ohio, Oregon, Rhode Island, South Dakota, Tennessee
2024-11-18
Recruiting
Regeneron Pharmaceuticals
Phase 3
975
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-10-30
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
240
California, Connecticut, Illinois, Michigan, New York, North Carolina, Pennsylvania, Texas
2024-09-23
Active, closed
Regeneron Pharmaceuticals
Phase 2
151
California, Colorado, Connecticut, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2024-09-18
Active, closed
Regeneron Pharmaceuticals
Phase 4
120
California, Colorado, Florida, Idaho, Illinois, Kansas, Kentucky, Maine
2024-08-26
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,126
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Maryland
2024-07-24
Active, closed
Regeneron Pharmaceuticals
Phase 2
195
Florida, Illinois, Kansas, Michigan, Missouri, New York, Oregon, Virginia
2024-07-16
Active, closed
Regeneron Pharmaceuticals
Phase 2
1,005
Alabama, Arizona, California, Florida, Georgia, Hawaii, Idaho, Illinois
2024-03-13
Active, closed
Regeneron Pharmaceuticals
Observational
11
Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana, Michigan, Ohio
2024-01-17
Recruiting
Regeneron Pharmaceuticals
Observational
20
California, Connecticut, Illinois, Maryland, Minnesota, New York, Pennsylvania
2023-10-19
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
160
Arizona, California, Colorado, Connecticut, Florida, Illinois, Louisiana, Mississippi
2023-08-08
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
149
Arizona, California, Connecticut, Florida, Illinois, Louisiana, Mississippi, Missouri
2023-06-30
Active, closed
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
NCT05831176Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
DrugDupilumab
Regeneron Pharmaceuticals
Phase 2
22
Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas, Massachusetts
2023-05-03
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,564
California, Colorado, Florida, Illinois, Massachusetts, Michigan, New Jersey, New York
2023-01-16
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
43
California, Connecticut, District of Columbia, Illinois, Maryland, Minnesota, New York, Pennsylvania
2022-08-02
Active, closed
Regeneron Pharmaceuticals
Phase 3
288
Arizona, California, Colorado, Florida, Illinois, Michigan, Ohio, Pennsylvania
2021-12-14
Active, closed
Regeneron Pharmaceuticals
Observational
717
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2021-08-12
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
548
California, Colorado, Florida, Illinois, Iowa, Michigan, New Jersey, New York
2020-12-21
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
612
California, Florida, Illinois, Massachusetts, Michigan, New York, Ohio, Pennsylvania
2020-12-08
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Illinois, Iowa, Kentucky, Massachusetts, Minnesota, New Jersey, New York, North Carolina
2019-11-13
Active, closed
Regeneron Pharmaceuticals
Phase 3
415
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland
2019-06-04
Active, closed
Regeneron Pharmaceuticals
Observational
858
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2018-04-06
Active, closed
Regeneron Pharmaceuticals
Phase 3
880
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2015-10-15
Rows per page Showing 1–32 of 32
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-usa/state/illinois

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 11 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 32 of those studies with a site in Illinois that also match the filters currently applied.

How many clinical trials are recruiting in Illinois?

12 of the 32 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 20 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Illinois), 32 studies
PhaseStudiesRecruitingShare
Phase 211534.4%
Phase 38325%
Observational5115.6%
Phase 1/25315.6%
Phase 2/3206.3%
Phase 4103.1%

Most active sponsors

Lead sponsors with the most studies (Illinois)
Lead sponsorStudiesRecruiting
Regeneron Pharmaceuticals3212
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.